Cargando…

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

BACKGROUND: To investigate the prognostic value of quality of life (QOL) relative to tumour marker carbohydrate antigen (CA) 19-9, and the role of CA 19-9 in estimating palliation in patients with advanced pancreatic cancer receiving chemotherapy. METHODS: CA 19-9 serum concentration was measured at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhard, J, Dietrich, D, Glimelius, B, Hess, V, Bodoky, G, Scheithauer, W, Herrmann, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990612/ https://www.ncbi.nlm.nih.gov/pubmed/20877359 http://dx.doi.org/10.1038/sj.bjc.6605929

Ejemplares similares

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
por: Gargiulo, Piera, et al.
Publicado: (2019)

Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy
por: Markus, M., et al.
Publicado: (2020)

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy
por: Huang, Pei‐Wei, et al.
Publicado: (2019)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.
por: Kornek, G., et al.
Publicado: (1995)

Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy
por: Ishizaki, Ayana, et al.
Publicado: (2023)

Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
por: Kim, Hong Jun, et al.
Publicado: (2020)

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy
por: Kim, Sungjin, et al.
Publicado: (2020)

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
por: Thol, Felix, et al.
Publicado: (2021)

Estimating the Number of Patients Receiving Specialized Palliative Care Globally in 2017
por: Connor, Stephen R., et al.
Publicado: (2021)

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
por: Pasanen, P. A., et al.
Publicado: (1993)

Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy
por: Lahner, Harald, et al.
Publicado: (2021)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Side effects during chemotherapy predict tumour response in advanced colorectal cancer
por: Schuell, B, et al.
Publicado: (2005)

The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis
por: Nordfors, Kristiina, et al.
Publicado: (2010)

2678. Characterizing Hospitalizations and Infections Among Older Adults Receiving Palliative Chemotherapy for Hematologic Malignancies
por: Uy, Natalie, et al.
Publicado: (2019)

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
por: Yoo, Shin Hye, et al.
Publicado: (2021)

Symptoms of total pain experienced by older people with advanced gastrointestinal cancer receiving palliative chemotherapy
por: Jespersen, Eva, et al.
Publicado: (2022)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Meridian energy analysis may predict the prognosis of patients with advanced cancers receiving palliative care
por: Chung, Ming-Cheng, et al.
Publicado: (2023)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.
por: Haglund, C., et al.
Publicado: (1986)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients
por: Xue, Peng, et al.
Publicado: (2014)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Malignant Pancreatic Polypeptide Secreting Tumour of Islet Cells: A Case for Aggressive Surgical Palliation
por: Pullan, R. D., et al.
Publicado: (1993)

Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy
por: Peng, Hong, et al.
Publicado: (2019)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours
por: Westgaard, Arne, et al.
Publicado: (2009)

Palliative chemotherapy: oxymoron or misunderstanding?
por: Roeland, EJ, et al.
Publicado: (2016)

Palliative chemotherapy in carcinoma nasopharynx
por: Patil, Vijay M., et al.
Publicado: (2019)

Accuracy of prognosis estimates by four palliative care teams: a prospective cohort study
por: Higginson, Irene J, et al.
Publicado: (2002)

Physicians’ perspectives on estimating and communicating prognosis in palliative care: a cross-sectional survey
por: Engel, Marijanne, et al.
Publicado: (2020)

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
por: Haglund, C., et al.
Publicado: (1986)

Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.
por: Kressner, U., et al.
Publicado: (1998)

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy
por: Kim, Jeong Eun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_el3an6ajo81pk24ejqu2db89qu